# Assessing the endothelium’s role in COVID-19 severity using the HUVEC model

**Authors:** Sanzio Silva Santana, Sètondji Cocou Modeste Alexandre Yahouédéhou, Corynne Stéphanie Ahouéfa Adanho, Jéssica Rebouças Silva, Hayna Malta Santos, Cynara Gomes Barbosa, Thassila Nogueira Pitanga, Valéria Matos Borges, Vitor Fortuna, Isa Menezes Lyra, Marilda Souza Goncalves

PMC · DOI: 10.3389/fimmu.2025.1689772 · Frontiers in Immunology · 2026-01-08

## TL;DR

This study uses human umbilical vein endothelial cells to show how blood serum from severe COVID-19 patients triggers strong inflammatory and oxidative responses in the endothelium, contributing to disease severity.

## Contribution

The study demonstrates that endothelial cells exposed to serum from severe COVID-19 patients exhibit a distinct inflammatory and oxidative gene and protein profile, offering a novel in vitro model for assessing endothelial involvement in disease severity.

## Key findings

- Serum from severe COVID-19 patients induces significant endothelial activation, inflammation, and oxidative stress within 60 minutes.
- Endothelial cells exposed to severe patient serum secrete elevated levels of cytokines, adhesion molecules, and growth factors linked to disease severity.
- P-selectin and MIP-1β are strong biomarkers distinguishing severe cases from healthy individuals.

## Abstract

Coronavirus disease 2019 (COVID-19) has been widely associated with intense systemic inflammation, endothelial injury, and a high incidence of thrombotic complications, which together contribute to disease severity and poor clinical outcomes. While endothelial dysfunction, dysregulated cytokine production, and oxidative stress are recognized features of severe COVID-19, the direct impact of circulating factors from infected individuals on endothelial cell behavior remains insufficiently characterized. Here, we examined how serum from patients with severe COVID-19 and from convalescent individuals modulates endothelial activation, inflammatory responses, and oxidative stress using human umbilical vein endothelial cells as an in vitro model.

Venous blood samples were collected from individuals with severe COVID-19 (n = 13), convalescent patients (n = 11), and healthy volunteers (n = 7) during the initial phase of the COVID-19 pandemic. Human umbilical vein endothelial cells (HUVEC) were maintained in culture and exposed to 15% serum from each study group after a period of serum deprivation. The expression of genes associated with endothelial activation, thrombosis, inflammation, and oxidative stress was analyzed by quantitative real-time PCR at defined time points. In addition, the endothelial secretory profile was evaluated in cell culture supernatants using multiplex bead-based immunoassays. Statistical analyses were performed using one-way ANOVA followed by appropriate post hoc tests, receiver operating characteristic (ROC) curve analysis to assess the discriminatory capacity of biomarkers, and multivariate linear regression to identify factors associated with disease severity.

We investigated the role of the endothelium in modulating the cytokine storm in severe COVID-19. HUVEC were stimulated with serum from patients with severe COVID-19, convalescent individuals, and healthy volunteers. Stimulation with serum from severe cases induces significant increases in VCAM1, F3, PROCR, IL6, IL12A, NFE2L2, HMOX1, GPX1, and GSR expression within 60 minutes. Antioxidant genes SOD1 and CAT were upregulated later, after 120 minutes. HUVEC stimulated with severe COVID-19 sera showed increased levels of sICAM-1, sVCAM-1, P-selectin, sE-selectin, PECAM-1, tissue factor, thrombomodulin, and a broad range of cytokines and growth factors, such as IL-1α, IL-1Ra, IL-5, IL-6, IL-10, IL-12(p40), IL-18, IL-27, TNF-α, TGF-α, FGF-2, G-CSF, M-CSF, FLT-3L, fractalkine, eotaxin, MIG, IP-10, MIP-1β, MDC, GROa and PDGF-AB/BB. In contrast, convalescent sera induced fewer markers, specifically IL-12(p40), IL-18, FGF-2, MIP-1β, MDC, GROa, and PDGF-AB/BB, while HV sera induced significant increases in IL-12(p40), IL-27, TNF-α, VEGF, MDC, eotaxin, and GROa. ROC curve analysis revealed that P-selectin and MIP-1β levels clearly distinguish severe cases from HV. When comparing severe and convalescent groups, we observed increases in IL-27, TGF-α, sVCAM-1, IL-1α, and G-CSF levels. Furthermore, Multivariable logistic regression analysis associated disease severity with decreased IL-10 and increased MIP-1β, sICAM-1, and P-selectin.

These findings suggest that HUVEC serves as a promising biological sensor for detecting inflammatory responses in COVID-19 patients and shows the crucial role of the endothelium in sustaining the cytokine storm that contributes to patient severity and mortality.

## Linked entities

- **Genes:** VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412], F3 (coagulation factor III, tissue factor) [NCBI Gene 2152], PROCR (protein C receptor) [NCBI Gene 10544], IL6 (interleukin 6) [NCBI Gene 3569], IL12A (interleukin 12A) [NCBI Gene 3592], NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780], HMOX1 (heme oxygenase 1) [NCBI Gene 3162], GPX1 (glutathione peroxidase 1) [NCBI Gene 2876], GSR (glutathione-disulfide reductase) [NCBI Gene 2936], SOD1 (superoxide dismutase 1) [NCBI Gene 6647], CAT (catalase) [NCBI Gene 847]
- **Proteins:** SELP (selectin P), PECAM1 (platelet and endothelial cell adhesion molecule 1), IL1A (interleukin 1 alpha), IL1R1 (interleukin 1 receptor type 1), IL5 (interleukin 5), IL6 (interleukin 6), IL10 (interleukin 10), Il12b (interleukin 12b), IL18 (interleukin 18), IL27 (interleukin 27), TNF (tumor necrosis factor), TGFA (transforming growth factor alpha), FGF2 (fibroblast growth factor 2), CSF3 (colony stimulating factor 3), CSF1 (colony stimulating factor 1), FLT3LG (fms related receptor tyrosine kinase 3 ligand), CX3CL1 (C-X3-C motif chemokine ligand 1), Ccl11 (C-C motif chemokine ligand 11), CXCL9 (C-X-C motif chemokine ligand 9), CXCL10 (C-X-C motif chemokine ligand 10), CCL4 (C-C motif chemokine ligand 4), ADAM11 (ADAM metallopeptidase domain 11), CXCL1 (C-X-C motif chemokine ligand 1)
- **Diseases:** COVID-19 (MONDO:0100096)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, IL12A (interleukin 12A) [NCBI Gene 3592] {aka CLMF, IL-12A, NFSK, NKSF1, P35}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, CAT (catalase) [NCBI Gene 847], SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, CX3CL1 (C-X3-C motif chemokine ligand 1) [NCBI Gene 6376] {aka ABCD-3, C3Xkine, CXC3, CXC3C, NTN, NTT}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, CCL22 (C-C motif chemokine ligand 22) [NCBI Gene 6367] {aka A-152E5.1, ABCD-1, DC/B-CK, MDC, SCYA22, STCP-1}, IL27 (interleukin 27) [NCBI Gene 246778] {aka IL-27, IL-27A, IL27A, IL27p28, IL30, p28}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, IL9 (interleukin 9) [NCBI Gene 3578] {aka HP40, IL-9, P40}, THBD (thrombomodulin) [NCBI Gene 7056] {aka AHUS6, BDCA-3, BDCA3, CD141, THPH12, THRM}, PROCR (protein C receptor) [NCBI Gene 10544] {aka CCCA, CCD41, EPCR}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, TGFA (transforming growth factor alpha) [NCBI Gene 7039] {aka TFGA}, GPX1 (glutathione peroxidase 1) [NCBI Gene 2876] {aka GPXD, GSHPX1}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, FLT3LG (fms related receptor tyrosine kinase 3 ligand) [NCBI Gene 2323] {aka FL, FLG3L, FLT3L, IMD125}, CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}
- **Diseases:** COVID-19 (MESH:D000086382), endothelial dysfunction (MESH:D014652), endothelial injury (MESH:D057772), inflammation (MESH:D007249), infected (MESH:D007239), thrombosis (MESH:D013927)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12823526/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12823526/full.md

## References

75 references — full list in the complete paper: https://tomesphere.com/paper/PMC12823526/full.md

---
Source: https://tomesphere.com/paper/PMC12823526